摘要
目的探讨肺癌肿瘤标志物细胞角蛋白19片段(CYFRA21-1)、癌胚抗原(CEA)和神经特异性烯醇化酶(NSE)在肺癌诊断中的应用。方法选取137例肺癌患者,根据病理分型、临床分期、治疗前后进行分组,选取健康体检者67例作为对照组,检测各组CYFRA21-1、CEA、NSE浓度。结果不同病理分型的CYFRA21-1(F=153.425,P=0.000)、CEA(F=126.974,P=0.000)、NSE(F=246.712,P=0.000)浓度差异均有统计学意义。不同临床分期的非小细胞肺癌的CYFRA21-1(F=183.059,P=0.000)、CEA(F=84.457,P=0.000)、NSE(F=188.058,P=0.000)浓度差异均有统计学意义,小细胞肺癌不同临床分期的CEA(F=82.104,P=0.000)、NSE(F=354.197,P=0.000)、CYFRA21-1(F=70.730,P=0.000)浓度差异有统计学意义(P<0.05)。治疗前后CYFRA21-1、CEA、NSE浓度差异均有统计学意义(P<0.05)。结论 CYFRA21-1、CEA、NSE可用于辅助预测肺癌的病理类型、临床分期、疗效评价。
Objective To explore the application of cytokeratin 19 fragment（CYFRA21-1）,carcinoembryonic antigen（CEA） and neuron specific enolase（NSE） in lung cancer.Methods One hundred and thirty seven patients with lung cancer were divided into different arms according to pathology,stage,before and after therapy,and tested the levels of CYFRA21-1,CEA and NSE,taken 67 healthy people as control arm.Results The levels of CYFRA21-1（F=153.425,P=0.000）,CEA（F=126.974,P=0.000）,NSE（F=246.712,P=0.000） existed significantly statistical differences in different types of pathology.The levels of CYFRA21-1（F=183.059,P=0.000）,CEA（F=84.457,P=0.000）,NSE（F=188.058,P=0.000）,CYFRA21-1（F=70.730,P=0.000） existed significantly statistical differences in different stages of non small-cell lung cancer,the levels of CEA（F=82.104,P=0.000）,NSE（F=354.197,P=0.000）,CYFRA21-1（F=70.730,P=0.0001） existed significantly statistical differences in different stages of small-cell lung cancer.Compared with before therapy and after therapy,the level of CYFRA21-1,CEA,NSE existed significantly statistical difference.Conclusion CYFRA21-1,CEA,NSE may assist to predict the pathology,stage and effect of therapy for lung cancer.
出处
《新疆医科大学学报》
CAS
2012年第10期1337-1340,共4页
Journal of Xinjiang Medical University
基金
国家自然科学基金(30360107)
